TGFB1 and neoplasm: Monoclonal antibody directed against B7-H4 have shown promising outcomes in inhibits tumor progression by blocking T-cell immunosuppression and augmenting antibody-dependent cellular cytotoxicity(ADCC) effects in OC, concurrently reducing the concentrations of VEGF and TGF-β within the TME (42, 70).